-+ 0.00%
-+ 0.00%
-+ 0.00%

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Benzinga·05/21/2025 12:45:41
Listen to the news
JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $86 price target.